Volume 9, Number 12—December 2003
Dispatch
Visceral Leishmaniasis Treatment, Italy
Table
First-line drugs used for treatment of visceral leishmaniasis in 533 immunocompetent patients in Italy and drug treatment failures recordeda
Y | MA (%) | L-AmB | ABCD | ABLC | dAmB | Any AmB drugs (%) |
---|---|---|---|---|---|---|
1995 |
57 (55.9)
3 R |
45
1 R |
0 |
0 |
0 |
45 (44.1)
1 R |
1996 |
35 (50.0)
2 R |
35
1 R |
0 |
0 |
0 |
35 (50.0)
1 R |
1997 |
26 (39.4)
3 U, 1 R |
34
2 R |
5 |
0 |
1 |
40 (60.6)
2 R |
1998 |
14 (28.0)
1 R |
32
1 R |
4 |
0 |
0 |
36 (72.0)
1 R |
1999 |
13 (21.0)
1 U, 1 R |
45
2 R |
2 |
1 |
1 |
49 (79.0)
2 R |
2000 |
11 (9.8)
1 U, 3 R |
89
1 U, 1 R |
10
1 U |
1
1 R |
1 |
101 (90.2)
2 U, 2 R |
2001 |
2 (2.8) |
68
1 R |
0 |
1 |
0 |
69 (97.2)
1 R |
Total | 158 (29.6) 5 U, 11 R | 348 1 U, 9 R | 21 1 U | 3 1 R | 3 | 375 (70.4) 2 U, 10 R |
aMA, meglumine antimoniate; L-AmB, liposomal amphotericin B; ABCD, amphotericin B colloidal dispersion; ABLC, amphotericin B lipid complex; dAmB, amphotericin B desoxycholate; U, unresponsiveness and/or acute toxicity; R, relapse.